Symposia: Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, Sickle Cell Disease, clinical trials, adult, Non-Biological therapies, Translational Research, Clinical Research, Hemoglobinopathies, drug development, Diseases, Gene Therapy, Therapies, Adverse Events, metabolism, Biological Processes, Technology and Procedures, Study Population, Human, omics technologies
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, Sickle Cell Disease, clinical trials, adult, Non-Biological therapies, Translational Research, Clinical Research, Hemoglobinopathies, drug development, Diseases, Gene Therapy, Therapies, Adverse Events, metabolism, Biological Processes, Technology and Procedures, Study Population, Human, omics technologies
Saturday, December 10, 2022: 9:30 AM-11:00 AM
391-392
(Ernest N. Morial Convention Center)
Moderator:
and
Kleber Yotsumoto Fertrin, MD, PhD, University of Washington
Disclosures:
Fertrin: Sanofi Genzyme: Consultancy; Agios Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Global Blood Therapeutics: Consultancy, Speakers Bureau.
This session will describe research and updated results of novel therapies for sickle cell disease.
9:30 AM
9:45 AM
10:00 AM
10:15 AM
10:30 AM
10:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH